Dougé Aurore, Ravinet Aurélie, Bay Jacques-Olivier, Tournilhac Olivier, Guièze Romain, Lemal Richard
CHU de Clermont-Ferrand, service d'hématologie clinique adulte et de thérapie cellulaire, 63003 Clermont-Ferrand, France; Clermont université, université d'Auvergne, EA7283, CIC501, BP 10448, 63000 Clermont-Ferrand, France.
CHU de Clermont-Ferrand, service d'hématologie clinique adulte et de thérapie cellulaire, 63003 Clermont-Ferrand, France; Clermont université, université d'Auvergne, EA7283, CIC501, BP 10448, 63000 Clermont-Ferrand, France.
Bull Cancer. 2016 Feb;103(2):127-37. doi: 10.1016/j.bulcan.2015.12.003. Epub 2016 Jan 25.
Ibrutinib is a new-targeted therapy that irreversibly and specifically inhibits the Bruton's Tyrosine Kinase (BTK), a key component of the signaling pathways of B cells. The results are very encouraging as monotherapy in the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenström's macroglobulinemia. Following the results of recent studies, ibrutinib is now available in France for these three diseases.
依鲁替尼是一种新型靶向疗法，它能不可逆且特异性地抑制布鲁顿酪氨酸激酶（BTK），BTK是B细胞信号通路的关键组成部分。作为单一疗法用于治疗慢性淋巴细胞白血病、套细胞淋巴瘤和华氏巨球蛋白血症，其效果非常令人鼓舞。根据近期研究结果，依鲁替尼目前在法国已可用于治疗这三种疾病。
Zotero 插件